Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines
Clinical trial NCT05024058 · TERMINATED
Trial details
- NCT number
- NCT05024058
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-16
- Primary completion
- 2022-08-09
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.